A Phase 1 interventional study of HPB-092 tablet in Relapsed and Refractory Acute Myeloid Leukemia (RR-AML), sponsored by Hangzhou Polymed Biopharmaceuticals, Inc.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by Hangzhou Polymed Biopharmaceuticals, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 265 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.
Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 181st largest by planned enrollment of the 433 interventional ones that give a count, is one of 56 that started in 2026, is one of 121 in phase 1, reaches primary completion later than 171 of the 288 other live ones, and was the 389th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →265 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18+
Beijing InnoCare Pharma Tech Co., Ltd. · Sites in China
Ages 18+
iCell Gene Therapeutics · Sites in China
Ages 18–70
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Sites in China
Ages 18+
Guangdong Second Provincial General Hospital · Sites in China
Ages 18–60
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
473 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 187 · Phase 2 191 · Phase 3 77 · Phase 4 13
First in 2003; this study’s year is marked. 56 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 50 across the 433 interventional studies, 100 across the 39 observational. Of the 72 that completed or were terminated, 9 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
115 of 473 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Hangzhou Polymed Biopharmaceuticals, Inc. as lead sponsor.
Hangzhou Polymed Biopharmaceuticals, Inc. has 1 study filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
71 of the studies in Leukemia, Myeloid, Acute with a site in China that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06802718Phase 3Peking University People's HospitalInterferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia | 2026-12 |
| NCT07712848Phase 3The Second Affiliated Hospital of Kunming Medical UniversityDEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML | 2026-12-01 |
| NCT07486479Phase 3The First Affiliated Hospital of Soochow UniversityVenetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML | 2026-12-31 |
| NCT06990321Phase 3Yehui TanEffectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia | 2026-12-31 |
| NCT06345365Phase 3Zhongnan HospitalMA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | 2026-12-31 |
Add all 71 to your calendar (.ics) → With an account.
Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
HPB-092 effectively inhibits Fms-like tyrosine kinase 3 (FLT3) mutants with comparable or superior potency to approved FLT3 inhibitors and demonstrates improved selectivity, potentially reducing toxicity. Its highly selective and potent inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) may provide additional therapeutic benefits that could enhance treatment efficacy and durability for patients with relapsed or refractory acute myeloid leukemia (RR-AML), further improving clinical outcomes in this population. HPB-092 also has a favorable safety profile, with no major risks identified in preclinical studies.
Phas 1 Study Outline:
HPB-092 - A Novel Dual Selective Kinase Inhibitor of FLT3 and IRAK4:
Multiple FLT3 inhibitors have been approved for clinical use in acute myeloid leukemia (AML). However, many patients do not benefit from these therapies due to toxicities and resistance. IRAK4 is a serine/threonine kinase involved in innate immune signaling. Overexpression of IRAK4-particularly the long isoform (IRAK4-L)-is common in most AML cases and is associated with poor prognosis and resistance to FLT3 inhibitors, suggesting that dual inhibition of FLT3 and IRAK4 may provide therapeutic benefits.
HPB-092 is an effective dual inhibitor of FLT3 and IRAK4, exhibiting high selectivity, favorable absorption, distribution, metabolism, and excretion (ADME) properties, as well as strong anti-leukemic efficacy. It also has a broader safety window in non-clinical studies compared to existing FLT3 inhibitors. Given its potential to address unmet medical needs in RR-AML patients, particularly those resistant to existing FLT3 inhibitors, HPB-092 warrants further clinical investigation.
Primary Objective and Endpoints:
The primary objective of this Phase 1 study is to evaluate the safety and tolerability of HPB-092 monotherapy in patients with RR-AML. The primary endpoints will include assessments of adverse events (AEs), treatment-emergent adverse events (TEAEs), dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD).
Secondary Objectives:
The secondary objectives of this Phase 1 study are as follows:
Exploratory Objectives:
The exploratory objectives will focus on the clinical pharmacology of HPB-092, including the identification of potential biomarkers to predict the response to HPB-092 in AML patients.
Part A Dosing Protocol:
HPB-092 is available in tablet form, with two strengths: 10 and 40 milligrams (mg). In Part A of the dose escalation, the starting dose will be 30 mg administered twice daily (BID), with subsequent dose escalations planned up to five dose levels. This approach aims to determine the Recommended Expansion Dose (RED) for the Part B dose expansion cohorts. Each treatment cycle will last 28 days and may be repeated in the absence of DLT or other toxicities, as determined by the investigator. Patients who derive clinical benefit from the study treatment may continue for up to two years from the initiation of the study drug or until one or more treatment discontinuation criteria are met.
In each dose escalation cohort, patients with RR-AML will be enrolled at the designated dose. Dose escalation will follow modified 3+3 rules, with DLT assessed during the first cycle. Escalation to the next dose level will occur as soon as the safety of the current dose is confirmed in a Cohort Review Meeting. The dose and schedule of HPB-092 administered to each patient will be documented on the appropriate form for each cycle.
Part B Dosing Protocol:
The Part B expansion, consisting of up to 3 dose levels, will begin once the recommended expansion doses (RED) is established based on the maximum tolerated dose (MTD) determined in Part A. This Part B expansion aims to further evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HPB-092, as well as to determine the recommended phase II dose (RP2D). The RP2D will be reviewed by a Cohort Review Meeting based on the results from Part B, considering all aspects of safety, tolerability, biological activity, pharmacokinetics, and preliminary efficacy in the trial population. The intent of the RP2D is to establish recommended dose levels and dosing intervals for the Phase II study, maximizing the potential for clinical benefit while minimizing the risk of toxicity. The Cohort Review Meeting may request the recruitment of additional patients at any previously explored or intermediate dose level to make an appropriate RP2D decision for the Phase 2 study.
Ethical Conduct of the Study:
The study will be conducted in accordance with the protocol, ICH guidelines, and applicable regulations governing clinical study conduct. Additionally, it will adhere to ethical principles derived from the Declaration of Helsinki.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
This study's planned enrollment of 60 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Browse Leukemia, Myeloid, Acute studies →This is the only study on the registry with Hangzhou Polymed Biopharmaceuticals, Inc. as lead sponsor.
Compared within Leukemia, Myeloid, Acute, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must meet all of the following inclusion criteria to be eligible for enrollment in the study:
The patient must have a diagnosis of morphologically documented acute myeloid leukemia (AML) according to the World Health Organization (WHO) 2022 criteria, and must meet one of the following conditions:
Relapsed Disease: Bone marrow blasts ≥ 5%; or Reappearance of blasts in the peripheral blood in at least two separate samples taken at least one week apart; or Development of extramedullary disease. Refractory Disease: Failure to achieve CR, CRh, or CRi at the response landmark (e.g., after 2 courses of intensive induction therapy), or Failure to achieve remission by a defined landmark, e.g., 180 days after initiation of less intensive therapy.
Exclusion Criteria:
Patients with any of the following characteristics/conditions will not be able to enroll in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RR-AML patients receive HPB-092 tablet monotherapy BID daily. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: HPB-092 tablet
HPB-092 is formulated as a tablet for oral administration, taken twice daily (BID) over consecutive 28-day cycles. This novel small molecule selectively inhibits both FLT3 and interleukin-1 receptor-associated kinase 4 (IRAK4). IRAK4 plays a crucial role in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways, which are frequently dysregulated in acute myeloid leukemia (AML) and other malignancies.
Adverse Events and Treatment-Emergent Adverse Events [Safety and Tolerability]
Adverse events (AEs) and treatment-emergent adverse events (TEAEs) will be measured by the number of participants who have received at least one dose of HPB-092. All AEs and TEAEs will be assessed and reported in accordance with the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Time frame: From the first dose (Cycle 1 day 1) of HPB-092 treatment until 28 days after the completion of treatment, or after early termination or withdrawal from the study, with a duration of up to 24 months
Dose-Limiting Toxicity [Safety and Tolerability]
The Dose-Limiting Toxicity (DLT) will be determined based on the first cycle (Days 1-28) of HPB-092 in RR-AML patients. Reviews of DLT for dose escalation decisions will be conducted for each completed dose level. Dose escalation decisions will require full safety data review of all subjects who completed Cycle 1 (Days 1-28) or discontinued due to a suspected DLT within Cycle 1 (Days 1-28).
Time frame: Days 1-28 of the first cycle (each cycle is 28 days)
Maximum Tolerated Dose [Safety and Tolerability]
The Maximum Tolerated Dose (MTD) is defined as the highest dose level at which ≤1 of 6 evaluable RR-AML subjects (≤33%) experience a DLT during Cycle 1 (Days 1-28). If ≥2 DLTs occur at a given dose level, the preceding dose will be expanded to 6 additional subjects for MTD confirmation. All subjects must complete the DLT observation period (Cycle 1, Days 1-28) to be evaluable; early discontinuations due to non-DLT reasons will be replaced.
Time frame: Days 1-28 of the first cycle (each cycle is 28 days)
Characterization of the pharmacokinetic (PK) parameters of HPB-092, measured by the maximum plasma concentration (Cmax), in AML patients.
Maximum plasma concentration (Cmax) in AML patients
Time frame: Up to 24 months
Characterization of the pharmacokinetic (PK) parameters of HPB-092, measured by Time to maximum plasma concentration (Tmax), in AML patients
Time to maximum plasma concentration (Tmax) in AML patients
Time frame: Up to 24 months
Characterization of the pharmacokinetic (PK) parameters of HPB-092, measured by Area under the plasma concentration versus time curve (AUC) [0-24], in AML patients
Area under the plasma concentration-time curve from 0 to 24 hours in AML patients
Time frame: Up to 24 months
Characterization of the pharmacokinetic (PK) parameters of HPB-092, measured by Area under the plasma concentration versus time curve (AUC) [0-inf], in AML patients
Area under the plasma concentration-time curve from 0 to infinity in AML patients
Time frame: Up to 24 months
Characterization of the pharmacokinetic (PK) parameters of HPB-092, measured by Plasma terminal elimination half-life (T1/2), in AML patients
Plasma terminal elimination half-life (T1/2) in AML patients
Time frame: Up to 24 months
Characterization of the pharmacokinetic (PK) parameters of HPB-092, measured by the plasma clearance (CL), in AML patients.
Calculation of the clearance (CL) of HPB-092 in AML patients, determined by the plasma drug concentration-time curve area under the curve (AUC) and the administered dose.
Time frame: Up to 24 months
Assessment of the Efficacy of Clinical Response to HPB-092 Monotherapy in AML Patients.
Definitions for treatment response will follow the 2022 recommendations for the diagnosis and management of AML in adults from an international expert panel on behalf of the European LeukemiaNet (ELN). The clinical response to HPB-092 monotherapy in AML patients will be evaluated by determining the percentage of patients who achieve any of the following outcomes: complete remission (CR), complete remission with partial hematologic recovery (CRh), complete remission with incomplete hematologic recovery (CRi). The Disease Control Rate (DCR) is defined as the confirmed remission rate, encompassing all complete responses (CR + CRh + CRi) in AML patients.
Time frame: up to 24 months
Assessment of the Duration of Response to HPB-092 Monotherapy in AML Patients.
Assessed by the Duration of Response (DoR) to HPB-092 monotherapy in AML patients. The DoR is defined as the time from the first documentation of a complete response (CR, CRh, or CRi) until the first occurrence of disease progression or relapse in AML patients.
Time frame: Up to 24 months
Assessment of the Time to Response to HPB-092 Monotherapy in AML Patients.
Time to Response (TTR) is defined as the duration from the initiation of HPB-092 monotherapy to the first documentation of a clinical response (including CR, CRh, or CRi) in AML patients.
Time frame: Up to 24 months
Determination of the Recommended Phase 2 Dose (RP2D) of HPB-092 Monotherapy in AML Patients.
The Recommended Phase 2 Dose (RP2D) will be determined during the Cohort Review Meeting, taking into account all aspects of safety, tolerability, biological activity, pharmacokinetics, and preliminary efficacy within the trial population. The aim of establishing an RP2D is to identify a dose and schedule that optimize the potential for clinical benefit while minimizing the risk of toxicity in AML Patients.
Time frame: Up to 24 months
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Jun 2027, 14 months after the start.
Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's planned 14 months is below that.
Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.